Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.
Both fractional doses of 17DD yellow fever vaccine were non-inferior to full doses in inducing initial seroconversion and support the use of fractional dose yellow fever vaccines among young children for outbreak response during supply shortages.
Abstract
Background
Fractional doses of yellow fever vaccines have been shown to be safe and immunogenic in randomised controlled trials in adults and children. However, little evidence still remains in children younger than 2 years. We assessed immunogenicity of one-fifth (0·1 mL) and one-half (0·25 mL) fractional doses compared with full doses of 17DD yellow fever vaccine in children aged 9-23 months in Kampala, Uganda.
Methods
This phase 4, single-blind, randomised clinical trial evaluating fractional dose 17DD yellow fever vaccine among children was conducted at three public-sector health facilities in Uganda. Eligible participants were aged 9-23 months at enrolment, had no history of yellow fever disease or vaccination, and did not meet the exclusion criteria. Children were enrolled in three age strata: 9-12 months, 13-18 months, and 19-23 months, and were randomly assigned (1:1:1) using block randomisation (block sizes of three and six) to one-fifth (0·1 mL), one-half (0·25 mL), or full (0·5 mL) doses of the 17DD yellow fever vaccine. Participants were followed up at 4 weeks (visit 1 [V1]), 1 year (visit 2 [V2]), and 13-48 months (visit 3 [V3]) after vaccination. The primary analysis included per-protocol participants who attended within the prespecified visit window; an intention-to-treat analysis was also conducted including all randomly assigned participants with available outcome data. Participants with missing serological data were excluded from the analysis at the corresponding visit. The primary outcome was non-inferiority in seroconversion (5 percentage-point margin) at V1 measured by 50% plaque reduction neutralisation test. This study is registered with ClinicalTrials.gov, NCT03725618, and is complete.
Findings
Between March 26, 2019, and May 11, 2021, 1784 participants were randomly assigned to either one-fifth dose (n=600), one-half dose (n=594), or full dose (n=590). The median (IQR) age at enrolment was 13 (11-18) months. Both fractional doses met the non-inferiority criterion compared with the full dose with no difference in seroconversion between one-fifth and full doses and -0·17 (95% CI -0·52 to 0·17) difference between one-half and full doses in the per-protocol population at V1. There was no difference between the one-fifth and full doses.
Interpretation
Both fractional doses of 17DD yellow fever vaccine were non-inferior to full doses in inducing initial seroconversion. The results support the use of fractional dose yellow fever vaccines among young children for outbreak response during supply shortages.
A phase III open-label study evaluated the immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in Japanese boys and girls. Japanese boys aged 9-15 years (n = 105) received a 3-dose (Day 1, Month 2, and Month 6) regimen; Japanese boys (n = 104) and girls aged 9-14 years (n = 105) received a 2-...
Yuzuru Takeuchi, Motoharu Yonekawa, S. Murata et al.· Japanese journal of infectio...· 0 citations
A reduced PCV13 1+1 schedule, primed at either 6 weeks or 14 weeks, maintained non-inferior serotype-specific GMCs relative to the PCV13 2+1 schedule up until age 5 years, supporting schedule transition in countries with well established PCV programmes.
Daniel Kapelus, C. Olwagen, A. Izu et al.· The Lancet Child & Adolescen...· 0 citations
A single dose of MenACYW-TT induced non-inferior immune responses and a comparable safety profile versus MenACYW-DT in children and adolescents aged 2-17 years was demonstrated.
Ashish Bavdekar, D. Chansinghakul, Ravi Mandyam Dhati et al.· Vaccine· 0 citations
Group B Streptococcus (GBS) disease is an increasing medical burden in adults. The present phase 1 trial evaluated an adjuvanted GBS vaccine (GBS-AlpN) containing N-terminal domains of four alpha-like proteins (AlpNs) (Alp1N, Alp2/3 N, RibN and AlpCN) in 60 healthy adults and 30 with obesity and/or type 2 diabetes (O/D...
Lidia Oostvogels, Azhar Alhatemi, Simon De Gussem et al.· Vaccine· 0 citations
BACKGROUND
Immunisation in pregnancy against group B streptococcus could reduce severe disease in early infancy; however, there are few data on the safety and immunogenicity of vaccines given to women living with HIV and their infants. We aimed to evaluate the safety, tolerability, and immunogenicity of the hexavalent...
R. Mboizi, M. Sekikubo, G. Businge et al.· Lancet. Infectious Diseases...· 2 citations
Summary Background Solid organ transplant (SOT) recipients are at increased risk of influenza-related complications and often exhibit suboptimal vaccine responses. While both high-dose (HD) and double-dose (DD) quadrivalent inactivated influenza vaccines (QIIV) aim to enhance immunogenicity compared to the standard dos...
Thanachote Arayanumas, K. Boonnak, S. Kantachuvesiri et al.· The Lancet Regional Health -...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.